Clinuvel Pharmaceuticals Ltd.
CUVL
NASDAQ·Healthcare·Medical - Pharmaceuticals·Mkt cap $328.8M
$6.52
▲ +3.82%
P/E
—
Mkt Cap
$328.8M
52-Wk Range
$5.95–$8.92
52-Week Range
$5.95 - $8.92
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 7.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
No forward estimates available
Value
Valuation data unavailable
Momentum
Weak
-7.5% over 3m
Quality
Mixed
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CUVL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
AUG 26, 2026
Reported EPS of $0.34 vs $0.35 consensus (-3.5% surprise). Revenue of $41.1M vs $42.2M expected (-2.8%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-3.5%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How CUVL stacks vs Medical - Pharmaceuticals
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.